GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-05 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Plane Poiseuille flow is flow created between two infinitely long parallel plates, separated by a distance h with a constant pressure gradient G = −dp/dx is applied in the direction of flow. The flow is essentially unidirectional because of infinite length. The Navier–Stokes equations reduce to
=== Four Conditions === Oven-dry (OD) is defined as the condition of an aggregate where there is no moisture within any part of the aggregate. This condition can be achieved in a laboratory by heating the aggregate to 220 °F (105 °C) for a period of time. Air-dry (AD) is defined as the condition of an aggregate in which there are some water or moisture in the pores of the aggregate, while the outer surfaces of it is dry. This is a natural condition of aggregates in summer or in dry regions. In this condition, an aggregate will absorb water from other materials added to the surface of it, which would possibly have some impact on some characters of the aggregate. Saturated surface dry (SSD) is defined as the condition of an aggregate in which the surfaces of the particles are "dry" (i.e., they will neither absorb any of the mixing water added; nor will they contribute any of their contained water to the mix), but the inter-particle voids are saturated with water. In this condition aggregates will not affect the free water content of a composite material. The water adsorption by mass (Am) is defined in terms of the mass of saturated-surface-dry (Mssd) sample and the mass of oven dried test sample (Mdry) by the formula:
Type A1: abnormal oral glucose tolerance test (OGTT), but normal blood glucose levels during fasting and two hours after meals; diet modification is sufficient to control glucose levels Type A2: abnormal OGTT compounded by abnormal glucose levels during fasting or after meals; additional therapy with insulin or other medications is required Diabetes which existed before pregnancy is also split up into several subtypes under this system:
=== Nutritional advantages and issues === Chelation in the intestinal tract is a cause of numerous interactions between drugs and metal ions (also known as "minerals" in nutrition). As examples, antibiotic drugs of the tetracycline and quinolone families are chelators of Fe2+, Ca2+, and Mg2+ ions. EDTA, which binds to calcium, is used to alleviate the hypercalcemia that often results from band keratopathy. The calcium may then be removed from the cornea, allowing for some increase in clarity of vision for the patient. Homogeneous catalysts are often chelated complexes. A representative example is the use of BINAP (a bidentate phosphine) in Noyori asymmetric hydrogenation and asymmetric isomerization. The latter has the practical use of manufacture of synthetic (–)-menthol.
Sources: en.wikipedia.org
== External links == Nerve+Growth+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P01138 (Human Beta-nerve growth factor) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P01139 (Mouse Beta-nerve growth factor) at the PDBe-KB.
=== Breast changes === 5-ARIs have a small risk of breast changes in men including breast tenderness and gynecomastia (breast development/enlargement). The risk of gynecomastia is about 1.3%. There is no association of 5-ARIs with male breast cancer.
== In plants == Plant-made pharmaceuticals (PMPs), also referred to as pharming, is a sub-sector of the biotechnology industry that involves the process of genetically engineering plants so that they can produce certain types of therapeutically important proteins and associated molecules such as peptides and secondary metabolites. The proteins and molecules can then be harvested and used to produce pharmaceuticals. Arabidopsis is often used as a model organism to study gene expression in plants, while actual production may be carried out in maize, rice, potatoes, tobacco, flax or safflower. Tobacco has been a highly popular choice of organism for the expression of transgenes, as it is easily transformed, produces abundant tissues, and survives well in vitro and in greenhouses. The advantage of rice and flax is that they are self-pollinating, and thus gene flow issues (see below) are avoided. However, human error could still result in modified crops entering the food supply. Using a minor crop such as safflower or tobacco avoids the greater political pressures and risk to the food supply involved with using staple crops such as beans or rice. Expression of proteins in plant cell or hairy root cultures also minimizes risk of gene transfer, but at a higher cost of production. Sterile hybrids may also be used for the bioconfinement of transgenic plants, although stable lines cannot be established. Grain crops are sometimes chosen for pharming because protein products targeted to the endosperm of cereals have been shown to have high heat stability.
Sources: en.wikipedia.org
=== Strontium === Strontium is naturally deposited in hydroxyapatite, the mineral component of bones and teeth, following its consumption in food and water. Each locale has a unique Sr isotope ratio and, therefore, the ratio found in a bone or enamel sample can be cross referenced against a record of environmental Sr ratios and assigned to a region. Dental enamel forms in childhood, therefore, Sr extracted from dental enamel reflects the environment in which an individual lived during infancy and childhood. Bone, however, is constantly being renewed and can therefore be used to infer the adult diet and location of the individual. As such, if the Sr ratios are the analogous in the bones and teeth, it can be inferred that an individual remained in the same general region throughout their life. If the ratios differ, the individual's birthplace and death place can be mapped, allowing inference of their movements. This has been applied to determine the functionality and significance of Stonehenge, finding that both the visitors and cattle used in feasting travelled great distances, with Sr ratios attributed to both Scotland and Wales.
==== Elimination ==== The mean elimination half-life of carvedilol following oral administration ranges from 7 to 10 hours. The pharmaceutical product is a mix of two enantiomorphs, R(+)-carvedilol and S(–)-carvedilol, with differing metabolic properties. R(+)-Carvedilol undergoes preferential selection for metabolism, which results in a fractional half-life of about 5 to 9 hours, compared with 7 to 11 hours for the S(-)-carvedilol fraction.
Humphreys' study has been criticized by sociologists and other social and behavioral scientists on ethical grounds in that he observed sexual acts by masquerading as a voyeur, "did not get his subjects’ consent, tracked down names and addresses through license plate numbers, and interviewed the men in their homes in disguise and under false pretenses." According to Jack Nusan Porter, a sociologist who knew Humphreys and studied under Howard S. Becker at Northwestern University from 1967 to 1971, "Humphreys was enormously influential on graduate students and younger scholars in the field of deviance, ethnography, and what we called 'participant observation'. True, today one could not do such research because there was no 'informed consent' but then again, in many cases, when doing research on deviant behavior, one will never get 'informed consent' so we miss out on a lot of important findings. He was a true pioneer and a hero to all of us in these fields." Humphreys' research materials, including detailed diagrams and maps of tearoom activity he observed, are housed in the collections at ONE National Gay & Lesbian Archives. By 2004, Tearoom Trade had sold more than 300,000 copies. Steven P. Schacht notes that this fact "makes it one of the best selling books ever written by a sociologist." The book was also published by Gerald Duckworth & Co. in British English, and in German by Ferdinand Enke Vertag. Both of these versions were published in 1974.
Moreover, the ability to perform high frequency fractionation immediately from the eluent of a nano-LC column has greatly increases peak resolution and improved the overall separation quality when compared to continuous flow nano-LC devices. An HPLC column was first built directly into a microfluidic device by using TPE instead of PDMS for the device fabrication. The additional strength of TPE made it capable of supporting the higher pressures needed for HPLC such that a single, microfluidic lab-chip could perform chemical separation, fractionation, and further droplet manipulation. In order to increase the quality of chromatographic output, sturdier devices made of glass have shown the ability to withstand far greater pressure than TPE. Achieving these higher pressures to increase the degree of separation and eliminating all dead volumes through immediate droplet formation has shown the potential for droplet microfluidics to expand and improve the capabilities of HPLC separations.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.